Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
The American Journal of Cardiology
|
January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)
Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Journal of the American College of Cardiology
|
April 23, 2003
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial
Robert P Giugliano, Matthew T Roe, Robert A Harrington, et al.
Circulation. Cardiovascular Interventions
|
May 11, 2016
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy
Christopher J Popma, Shi Sheng, Serge Korjian, et al.
The New England Journal of Medicine
|
March 27, 2012
Vorapaxar in the secondary prevention of atherothrombotic events
David A Morrow, Eugene Braunwald, Marc P Bonaca, et al.
Thrombosis and Haemostasis
|
January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy
Robert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.
Journal of the American College of Cardiology
|
November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)
David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
Lancet (London, England)
|
March 23, 2017
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
E Magnus Ohman, Matthew T Roe, P Gabriel Steg, et al.
American Heart Journal
|
August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design
Sneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
Archives of Physiotherapy
|
December 10, 2021
Protocol for a multicenter, randomised controlled trial of surgeon-directed home therapy vs. outpatient rehabilitation by physical therapists for reverse total shoulder arthroplasty: the SHORT trial
June S Kennedy, Emily K Reinke, Lisa G M Friedman, et al.
The New England Journal of Medicine
|
November 15, 2011
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
Pierluigi Tricoci, Zhen Huang, Claes Held, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
The American Journal of Cardiology
|
January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)
Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Journal of the American College of Cardiology
|
April 23, 2003
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial
Robert P Giugliano, Matthew T Roe, Robert A Harrington, et al.
Circulation. Cardiovascular Interventions
|
May 11, 2016
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy
Christopher J Popma, Shi Sheng, Serge Korjian, et al.
The New England Journal of Medicine
|
March 27, 2012
Vorapaxar in the secondary prevention of atherothrombotic events
David A Morrow, Eugene Braunwald, Marc P Bonaca, et al.
Thrombosis and Haemostasis
|
January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy
Robert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.
Journal of the American College of Cardiology
|
November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)
David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
Lancet (London, England)
|
March 23, 2017
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
E Magnus Ohman, Matthew T Roe, P Gabriel Steg, et al.
American Heart Journal
|
August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design
Sneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
Archives of Physiotherapy
|
December 10, 2021
Protocol for a multicenter, randomised controlled trial of surgeon-directed home therapy vs. outpatient rehabilitation by physical therapists for reverse total shoulder arthroplasty: the SHORT trial
June S Kennedy, Emily K Reinke, Lisa G M Friedman, et al.
The New England Journal of Medicine
|
November 15, 2011
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
Pierluigi Tricoci, Zhen Huang, Claes Held, et al.
Page
of 5